Lung function decline in COPD trials: bias from regression to the mean

Suissa S.

Source: Eur Respir J 2008; 32: 829-831
Journal Issue: October
Disease area: Airway diseases

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Suissa S.. Lung function decline in COPD trials: bias from regression to the mean. Eur Respir J 2008; 32: 829-831

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Lung function decline in COPD trials
Source: Eur Respir J 2009; 33: 708-709
Year: 2009


Relationship of baseline or annual change of clinical parameters on mortality in patients with COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013

Estimating lung function decline and the effect of smoking in COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 578s
Year: 2002

Hierarchical linear models for longitudinal change in COPD - is there an effect of differential dropout between treatment groups on estimated decline rates?
Source: Eur Respir J 2001; 18: Suppl. 33, 151s
Year: 2001

Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016

Airway responsiveness predicts lung function decline differently in subjects with or without asthma: An international study
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013

Comparison of regression models for developing spirometric reference values
Source: International Congress 2016 – Functional assessment of the airways
Year: 2016


Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Dealing with missing longitudinal FEV1 observations when used as time-dependent covariate data in survival analysis for COPD patients within a regional UK population-level database
Source: International Congress 2015 – Epidemiology of respiratory disease
Year: 2015


Lung function decline in asthma
Source: Eur Respir J 2007; 30: 411-413
Year: 2007


Is physical activity a determinant for change in FEV1 in COPD patients? A prospective cohort study
Source: International Congress 2015 – Best abstracts in physical activity in chronic lung diseases
Year: 2015

Predictors of lung function decline: a retrospective study in COPD patients
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018


Predictors of lung function deterioration in COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


Correlation of nutritional status using subjective global assessment (SGA) on pulmonary function parameters in patients with COPD at the Philippine Heart Center
Source: Annual Congress 2013 –Disease control and quality of life in airway diseases
Year: 2013


Lung clearance index is increased in patients with COPD
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015

CPOD and lung function parameters as predictors of mortality: Results from the Latin American PLATINO cohort study
Source: International Congress 2014 – Longitudinal studies of respiratory disease
Year: 2014


Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – IPF treatment I
Year: 2016


FEV6: a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004

Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021


Predicting IPF outcomes: lung function evaluation by %predicted and z-score
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021